IngentaConnect Resiquimod, a new immune response modifier from the family of imi...

Authors: D. Quarcoo¹; S. Weixler¹; R.A. Joachim²; P. Stock¹; T. Kallinich; B. Ahrens¹; E. Hamelmann

Source: Clinical & Experimental Allergy, Volume 34, Number 8, August 2004 , pp. 1314-1320(7)

Abstract:

Summary Background

Allergen-induced sensitization and airway disease are the results of adverse immune reactions against environmental antigens that may be prevented or inhibited by immune modifying strategies. Objective

To investigate the effects of the novel immune response modifier resiquimod (R-848), from the family of imidazol-derivates, in a murine model of allergen-mediated Th2-immune responses and concomitant airway inflammation and airway hyper-reactivity. Methods

BALB/c mice were systemically sensitized with ovalbumin (OVA) on days 1 and 14 and challenged with OVA aerosol on days 28 and 29. R-848 was applied intranasally to sensitized animals once prior to the first allergen airway challenge, on day 27. Results

A single application of R-848 significantly reduced numbers of eosinophils and lymphocytes in bronchoalveolar lavage fluid and inhibited mucus gland hyperplasia, compared with sensitized and challenged controls. Associated with the decrease in airway inflammation, single intranasal treatment with R-848 abolished the development of airway hyper-reactivity after allergen sensitization and airway challenges. Additionally, Th2-cytokine production in lung tissues from sensitized and R-848-treated animals was reduced, whereas IL-12 and IFN- gamma

production was increased, compared with non-treated sensitized mice. Conclusion

These data indicate that R-848 effectively inhibits allergen-induced airway inflammation and hyper-reactivity by modulation of increased Th2-immune responses.

Keywords: allergy; asthma; cytokine; eosinophils; immune response modifier; inflammation; lung; mice; ovalbumin

Document Type: Research article

DOI: 10.1111/j.1365-2222.2004.02023.x

Affiliations: 1: Pediatric Pneumology and Immunology and 2: Internal Medicine, Charité- Humboldt University, Berlin, Germany

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy

Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice